Bonesupport Holding AB banner

Intrinsic Value

The intrinsic value of Bonesupport Holding AB (BOEUF) under the Base Case is 49.034 USD per share. Compared with the current market price of 31.865 USD, the stock appears Undervalued by 35% .

The intrinsic value is calculated using the DCF method.

Do our valuations actually work? See backtest results .

BOEUF Intrinsic Value
$49.034
Undervaluation 35%
Intrinsic Value
Price $31.865
Alert me when BOEUF is below its intrinsic value
Today $29.420 · 7.7% below the current price

BOEUF is valued in line with its history. A discount of this size has been typical over the past 5 years.

Alternatives to BOEUF

Fundamental Analysis

What Bonesupport Holding AB Does

Biotechnology Health Care

Bonesupport Holding AB makes injectable bone graft substitutes that surgeons use to fill bone voids and help damaged bone heal. Its main products are sold under the CERAMENT name and are used in orthopedic procedures such as trauma, bone infection, foot and ankle surgery, and some spine cases. The company’s customers are hospitals, surgeons, and healthcare systems that buy these products through direct sales or distributors.

Headquarters
Sweden SE
Employees
160
IPO date
Jun 21, 2017
Read the full company overview
View Company Overview

Bonesupport Holding has a wide economic moat

No Moat Narrow Wide

Bonesupport Holding AB possesses a wide economic moat, providing strong and durable advantages that protect its market position and profitability.

Read the full moat analysis
Financials
Efficiency

Wall St Price Targets

Shareholder Returns

Competitive Landscape

Continue BOEUF Research

Decided on Bonesupport Holding? Get an email when BOEUF reaches the price you’d buy at. Free with an account.

Other Bonesupport Holding listings

What is the Intrinsic Value of one BOEUF stock?

The intrinsic value for Bonesupport Holding AB (BOEUF) under the Base Case is 49.034 USD.

Is BOEUF stock undervalued or overvalued?

Compared with the current market price of 31.865 USD, the stock appears Undervalued by 35% .

How reliable are our estimates? See how past valuations played out
Back to Top